comparemela.com

Page 7 - U11248 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BTKi Combo Strong Option in CLL

A new interim analysis finds more evidence that ibrutinib plus rituximab is a viable option for younger patients with untreated chronic lymphocytic leukemia compared with standard chemoimmunotherapy.

Rituximab Inferior to Ocrelizumab for MS Relapse

CLL: Venetoclax-Obinutuzumab Combo Effective Long Term

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.